Quick Details
- Processing Time:5 days for ready stock, 3 weeks for order
- Port:any port to be confirmed
- Supply Ability: 2000 Kilograms Per Month
- Appearance:off-white powder
- Application:Sulfonamide antiseizure agent; blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents. Heterocyclic methanesulfonide with anticonvulsant properties. The compound is under investigation for
- Brand Name:HRD
- CAS No.:68291-97-4
- EINECS No.:614-395-8
- Other Names:CI-912; AD-810; CI 912; Exceglan; Excegram; Excegran; Zonegran; PD 110843; Excegran (TN); Zonisamidum [Latin]; Zonisamida [Spanish]; AD 810 (sulfonamide); Zonisamide (JAN/USAN); Zonisamide [USAN:BAN:INN:JAN]; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 1,2-Benzisoxazole-3-methanesulfonamide; benzo[d]isoxazol-3-ylmethanesulfonamide
- Place of Origin:China
- Purity:99%
- Brand Name:HRD
Classification: Others
Cas NO.: 68291-97-4
Molecular Formula: C8H8N2O3S
Melting Point: 275°C dec.
Boiling Point: 457
Stability: null
Refractive index:
Flash Point: 230
Purity: 99%
Appearance: off-white powder
usage: synthesis of Zonisamide API
Brand Name: HRD
EINECS: 614-395-8
Aliase: 1-(1,2-Benzoxazol-3-yl)methanesulphonamide
Purity: 99%
Appearance:white crystalline powder
Brand: HRD
synthesis of Zonisamide API: anti-convulsant
Usage: Sulfonamide antiseizure agent; blocks repetitive firing of voltagesensitive sodium channels
and reduces voltage-sensitive T-type calcium currents. Heterocyclic methanesulfonide with anticonvulsant properties. The compound is under investigation for
Packaging & Delivery
Packaging Detail: 25kg per drum or as per the requirment of customer
Delivery Detail: 5 days for ready stock, 3 weeks for order.
Detailed Description
Synonyms: 1-(1,2-Benzoxazol-3-yl)methanesulphonamide
Main Specifications:
Appearance: white crystalline powder
Assay: 99% Min. HPLC
Single Impurity: 0.5% Max.
Loss on Drying: 0.5% Max.
Heavy Metal: 20ppm Max.
Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunct therapy in adults with
partial-onset seizures. Zonisamide is approved in the United States, United Kingdom, China, for adjunctive treatment of partial seizures in adults and in Japan for both adjunctive and monotherapy
for partial seizures (simple,complex, secondarily generalized), generalized (tonic, tonic-clonic(grand mal), and atypical absence) and combined seizures.
